Main Article Content

Abstract

Introduction


Affordability determines accessibility to drugs in developing countries. Variation in the cost of drugs is noted to be high in India, which can affect drug compliance. Acid Peptic disorders are prevalent in India and require long term therapy. Hence the present study was undertaken to analyse the cost variation of various brands of anti-ulcer drugs currently available in India.


Materials & methods


The drugs listed under the section “Antacids and Anti-ulcer agents” in Current Index of Medical Specialties (CIMS) October 2016-January 2017 edition was noted to analyze the variation in drug prices of various brands of drugs available in India. Further analysis was done by using Percentage Cost Variation.


Results


Wide variation in the prices of Antacids and anti-ulcer agents was noted. Among the H2 (Histamine 2) receptor blockers, the maximum percentage of cost variation was noted with Ranitidine (50 mg injection) 871.54%, and among proton pump inhibitors (PPIs), it was noted with Pantoprazole (40 mg EC-Tab) 500.75%. Among the PPIs, lowest percentage of cost variation was noted with Omeprazole 40 mg injection; among the H2 blockers, it was Ranitidine 300mg FC-TAB.


Among the Fixed Dose combinations (FDCs), maximum and minimum % of cost variation was noted with Ranitidine 150mg+Domperidone 10mg TAB (242%) and Pantoprazole 40mg+Domperidone 30mg SR-CAP (1%) respectively.  


Conclusion


More than 100% cost variation was seen with different brands of all PPIs and H2 receptor blockers.

Keywords

Anti-ulcer drugs Cost analysis Cost ratio Cost variation

Article Details

How to Cite
SnehaJyothi A N, & Divya R. (2021). Drug pricing of various formulations used for the management of acid peptic disorders. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(3), 319-326. https://doi.org/10.61096/ijrpp.v6.iss3.2017.319-326

References

  1. [1]. Dutta A, Chacko A, Balekuduru A, Sahu M, Gangadharan S. Time trends in epidemiology of peptic ulcer disease in India over two decades. Indian Journal of Gastroenterology. 31(3), 2012, 111-115.
  2. [2]. Di Saverio S, Bassi M, Smerieri N, Masetti M, Ferrara F, Fabbri C, et al. Diagnosis and treatment of perforated or bleeding peptic ulcers: 2013 WSES position paper. World J Emerg Surg. 9(1), 2014, 45.
  3. [3]. Measuring medicine prices, availability, affordability and price components [Internet]. WHO. 2017 [cited 2017]. Available from: http://apps.who.int/iris/bitstream/10665/70013/1/WHO_PSM_PAR_2008.3_eng.pdf
  4. [4]. Sakthivel S. Access to essential drugs and medicines. In: Lal PG, Byword editorial consultants, editors. National Commission on Macroeconomics and Health. Financing and delivery of health care services in India. New Delhi: Ministry of Health & Family Welfare, Government of India; 2005, 185-210.
  5. [5]. Kaiser Family Foundation. 2015. Available at https:// www.kff.org./health-costs/report/the-burden-of-medical-debt-results-from-the-kaiser-family-foundationnew-york-times-medical-bills-survey/.
  6. [6]. Peura DA, Berardi RR, Gonzalez J, Brunetti L. The value of branded proton pump inhibitors: formulary considerations. P T [Internet]. 36(7), 2011, 434–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21931475%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3171810
  7. [7]. Dyspepsia and gastro-oesophageal reflux disease - NICE Pathways [Internet]. Pathways.nice.org.uk. 2017 [cited 2017]. Available from: http://pathways.nice.org.uk/pathways/dyspepsia-and-gastro-oesophageal-reflux-disease
  8. [8]. Stedman CAM, Barclay M. L, Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors, AP & T. 14(8), 2000, 963–978.
  9. [9]. Kaur S, Rajagopalan S, Kaur N, Shafiq N, Bhalla A, Pandhi P et al Drug Utilization Study in Medical Emergency Unit of a Tertiary Care Hospital in North India Emergency Medicine International. 2014; Article ID 973578, 5 pageshttp://dx.doi.org/10.1155/2014/973578
  10. [10]. Patel M K, Barvaliya M J, Patel T K, Tripathi CB, Drug utilization pattern in critical care unit in a tertiary care teaching hospital in India.Int J CritIllnInj Sci. 3(4), 2013, 250–255.
  11. [11]. Roy V, Gupta U, Agarwal A K Cost of medicines & their affordability in private pharmacies in Delhi. Indian J Med Res. 136, 2012, 827-835.
  12. [12]. Iyengar S, Tay-Teo K, Vogler S, Beyer P,Wiktor S, de Joncheere K, et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 13(5), 2016, e1002032. doi:10.1371/journal.pmed.1002032.
  13. [13]. Balasubramaniam K. Is equitable pricing the answer? HAI NEWS, 2001, 118 (available at http://www.haiweb.org/pubs/hainews/200107_1.html, accessed 2005).
  14. [14]. Kamath L and Satish GR: Cost Variation Analysis of Antihypertensive Drugs Available in Indian Market: An Economic Perspective. Int J Pharm Sci Res 7(5), 2016, 2050-56.
  15. [15]. Wagle L, Swammy MK: Cost variation study of antiepileptic drugs available in India: Asian J Pharm Clin Res. 9(2), 2016, 64–8.
  16. [16]. Patel BS, Chavda FM, Mundhava SG: Cost variation analysis of single nonsteroidal anti-inflammatory agents available in Indian market : an economic perspective. IJPSR. 7(5), 2016, 13040.
  17. [17]. Monaghan MJ, Monaghan MS. Do market components account for higher US prescription prices. Ann Pharmacother 30, 1996, 1489-94.